
Moderna COVID-19 vaccine candidate adds to hope for pandemic endpoint
A second COVID-19 vaccine candidate, this one from Moderna, is showing 94.5 percent efficacy based on interim data from a late-stage trial, opening the possibility of two vaccines being available for distribution as early as next month.







